XML 50 R39.htm IDEA: XBRL DOCUMENT
v3.21.2

License and Collaboration Agreements - Additional Information (Detail) - USD ($) |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Feb. 13, 2018 | Aug. 23, 2017 | Apr. 30, 2018 | Sep. 30, 2017 | Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2018 | Dec. 31, 2020 | Jan. 09, 2020
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenue recognized in period related to performance in prior periods |  |  |  |  | $ 20,500,000 | $ 42,100,000 | $ 39,300,000 | $ 86,700,000 |  |  |
Potential future additional development and regulatory milestones (up to) |  |  |  |  | 1,700,000,000 |  | 1,700,000,000 |  |  |  |
Accounts receivable |  |  |  |  | 28,871,000 |  | 28,871,000 |  |  | $ 38,889,000 |
Bristol-Myers Squibb Company | Purchase Agreement |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Shares issued (in shares) |  |  | 8,284,600 |  |  |  |  |  |  |  |
Sale of stock consideration received |  |  | $ 850,000,000.0 |  |  |  |  |  |  |  |
Bristol Myers Squibb Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales milestone, revenue |  |  |  |  |  | 25,000,000.0 |  | 50,000,000.0 |  |  |
Bristol Myers Squibb Collaboration Agreement | Bristol-Myers Squibb Company | Purchase Agreement |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total consideration received under agreements |  |  |  |  |  |  |  |  | $ 1,850,000,000 |  |
Estimated fair value of shares |  |  |  |  |  |  |  |  | 790,200,000 |  |
Remaining amount allocated to transaction price |  |  |  |  |  |  |  |  | $ 1,059,800,000 |  |
Nektar-358 | Nektar's |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  | $ 150,000,000.0 |  |  |  |  |  |  |
Percentage of sharing in Phase 2 development costs |  | 25.00% |  |  |  |  |  |  |  |  |
Nektar-358 | Eli Lilly and Company | Maximum |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Potential future additional development and regulatory milestones (up to) |  | $ 250,000,000.0 |  |  |  |  |  |  |  |  |
Nektar-358 | Eli Lilly and Company | Nektar's |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Percentage of regulatory milestones payments will be reduced under certain conditions |  | 50.00% |  |  |  |  |  |  |  |  |
Percentage of regulatory milestones payments will be reduced if conditions occur |  | 75.00% |  |  |  |  |  |  |  |  |
Nektar-358 | Eli Lilly and Company | Nektar's | Maximum |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Percentage of funding phase 3 development costs on an indication by indication basis borne |  | 25.00% |  |  |  |  |  |  |  |  |
Nektar-358 | Eli Lilly and Company | Nektar's | Minimum |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Percentage of funding phase 3 development costs on an indication by indication basis borne |  | 0.00% |  |  |  |  |  |  |  |  |
Nektar-358 | Eli Lilly |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Percentage of sharing in Phase 2 development costs |  | 75.00% |  |  |  |  |  |  |  |  |
Other | Nektar's |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones (up to) |  |  |  |  | 40,000,000.0 |  | 40,000,000.0 |  |  |  |
Nektar 214 | Bristol-Myers Squibb Company | Research and Development Expense |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Reimbursement of expenses |  |  |  |  | 24,800,000 | $ 33,900,000 | 51,400,000 | $ 65,100,000 |  |  |
Nektar 214 | Bristol Myers Squibb Collaboration Agreement | Nektar's |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Global commercialization profits and losses sharing percentage | 65.00% |  |  |  |  |  |  |  |  |  |
Percentage of sharing production costs | 65.00% |  |  |  |  |  |  |  |  |  |
Upfront and milestone payments received from license agreements |  |  | 1,000,000,000.0 |  |  |  |  |  |  |  |
Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones |  |  |  |  |  |  | 1,455,000,000 |  |  |  |
Nektar 214 | Bristol Myers Squibb Collaboration Agreement | Nektar's | Milestone One |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones (up to) |  |  |  |  |  |  |  |  |  |  | $ 25,000,000.0
Potential development milestones excluded from transaction price (up to) |  |  |  |  | $ 1,800,000,000 |  | $ 1,800,000,000 |  |  |  |
Nektar 214 | Bristol Myers Squibb Collaboration Agreement | Nektar's | Maximum |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Eligible additional cash payments receivable upon achievement of certain sales milestones |  |  | $ 350,000,000.0 |  |  |  |  |  |  |  |
Nektar 214 | Bristol Myers Squibb Collaboration Agreement | Nektar's | Opdivo |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Percentage of sharing development costs | 32.50% |  |  |  |  |  |  |  |  |  |
Nektar 214 | Bristol Myers Squibb Collaboration Agreement | Bristol-Myers Squibb Company |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Global commercialization profits and losses sharing percentage | 35.00% |  |  |  |  |  |  |  |  |  |
Percentage of sharing production costs | 35.00% |  |  |  |  |  |  |  |  |  |
Nektar 214 | Bristol Myers Squibb Collaboration Agreement | Bristol-Myers Squibb Company | Opdivo |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Percentage of sharing development costs | 67.50% |  |  |  |  |  |  |  |  |  |
Nektar 358 License | Eli Lilly and Company |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Amount of transaction price allocated to performance obligation |  |  |  | 125,900,000 |  |  |  |  |  |  |
Nektar 358 License | Phase 1 Clinical Development | Eli Lilly and Company |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Amount of transaction price allocated to performance obligation |  |  |  | 17,600,000 |  |  |  |  |  |  |
Nektar 358 License | Drug Product Development | Eli Lilly and Company |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Amount of transaction price allocated to performance obligation |  |  |  | $ 6,500,000 |  |  |  |  |  |  |

X
- Definition Aggregate consideration received from agreements. + References No definition available. + Details
Name: | nktr_AggregateConsiderationReceivedFromAgreements
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation. + References No definition available. + Details
Name: | nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones. + References No definition available. + Details
Name: | nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Eligible additional cash payments receivable upon achievement of certain sales milestones. + References No definition available. + Details
Name: | nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Estimated fair value of shares. + References No definition available. + Details
Name: | nktr_EstimatedFairValueOfShares
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Percentage of development milestones payments, to be received, if conditions occur. + References No definition available. + Details
Name: | nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur
Namespace Prefix: | nktr_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of development milestones payments, to be received under certain conditions. + References No definition available. + Details
Name: | nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions
Namespace Prefix: | nktr_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of funding Phase three development costs on an indication by indication basis borne. + References No definition available. + Details
Name: | nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne
Namespace Prefix: | nktr_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of sharing in development costs. + References No definition available. + Details
Name: | nktr_PercentageOfSharingInDevelopmentCosts
Namespace Prefix: | nktr_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of sharing in Phase 2 development costs. + References No definition available. + Details
Name: | nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts
Namespace Prefix: | nktr_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of sharing in production costs. + References No definition available. + Details
Name: | nktr_PercentageOfSharingInProductionCosts
Namespace Prefix: | nktr_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential development and regulatory milestones. + References No definition available. + Details
Name: | nktr_PotentialDevelopmentAndRegulatoryMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential development milestones. + References No definition available. + Details
Name: | nktr_PotentialDevelopmentMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Potential Development Milestones Excluded from Transaction Price + References No definition available. + Details
Name: | nktr_PotentialDevelopmentMilestonesExcludedFromTransactionPrice
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Profits and losses sharing percentage. + References No definition available. + Details
Name: | nktr_ProfitsAndLossesSharingPercentage
Namespace Prefix: | nktr_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reimbursement of expenses. + References No definition available. + Details
Name: | nktr_ReimbursementOfExpenses
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Remaining amount allocated to transaction price. + References No definition available. + Details
Name: | nktr_RemainingAmountAllocatedToTransactionPrice
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sale of stock consideration received. + References No definition available. + Details
Name: | nktr_SaleOfStockConsiderationReceived
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sales Milestone Revenue + References No definition available. + Details
Name: | nktr_SalesMilestoneRevenue
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront and milestone payments received from license agreements. + References No definition available. + Details
Name: | nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront and milestone payments received under license agreement. + References No definition available. + Details
Name: | nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12A -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL108322424-203045 + Details
Name: | us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644 + Details
Name: | us-gaap_SharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_EliLillyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_OtherPartnerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=nktr_Nektar214Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nktr_MilestoneAxis=nktr_MilestoneOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=nktr_Nektar358LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_PhaseOneClinicalDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_DrugProductDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |